Selective insulin resistance with differential expressions of IRS-1 and IRS-2 in human NAFLD livers
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
BACKGROUND/OBJECTIVE: Insulin signals, via the regulation of key enzyme expression, both suppress gluconeogenesis and enhance lipid synthesis in the liver. Animal studies have revealed insulin signaling favoring gluconeogenesis suppression to be selectively impaired in steatotic livers. However, whether, and if so how, such selective insulin resistance occurs in human steatotic livers remains unknown. Our aim was to investigate selective insulin resistance in human livers with non-alcoholic fatty liver disease (NAFLD). SUBJECTS/METHODS: We examined mRNA expressions of key molecules for insulin signaling, gluconeogenesis and lipogenesis in human liver biopsy samples obtained from 51 non-diabetic subjects: 9 healthy controls and 42 NAFLD patients, and analyzed associations of these molecules with each other and with detailed pathological and clinical biochemistry data. RESULTS: In NAFLD patients, insulin receptor substrate (IRS)-2 expression was decreased, while those of key enzymes for gluconeogenesis were increased. These alterations of IRS-2 and gluconeogenesis enzymes were induced both in simple steatosis (SS) and non-alcoholic steatohepatitis (NASH), while these expression levels did not differ between SS and NASH. Furthermore, alterations in the expressions of IRS-2 and gluconeogenesis enzymes showed strong negative correlations and were concurrently induced in the early histological stage of NAFLD. In contrast, fatty acid synthase (FAS) expression was not decreased in NAFLD, despite IRS-2 downregulation, but correlated strongly with IRS-1 expression. Furthermore, no histological scores were associated with these molecules. Thus, IRS-1 signaling, which is not impaired in NAFLD, appears to modulate FAS expression. CONCLUSION: These analyses revealed that selective insulin resistance is present in human NAFLD livers and occurs in its early phases. The effect of insulin, during the IRS step, on gene expressions for lipogenesis and gluconeogenesis are apparently distinct and preferential downregulation of IRS-2 may contribute to selective resistance to the suppressive effects of insulin on gluconeogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies suggest that IRS1 and IRS2 have distinct roles in regulating hepatic lipid metabolism [20,30,97].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [97]
Experimental — accuracy not yet measuredIn the citing paper
“Decreased IRS2 expression but preserved IRS1 levels in the liver under hyperinsulinemia, HFD conditions, or in human MASLD [20,97], is associated with increased hepatic SREBP1c and DNL, whereas IRS1 deletion reduces DNL and TG content without altering SREBP1c levels.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [97]
In the citing paper
“Decreased IRS2 expression but preserved IRS1 levels in the liver under hyperinsulinemia, HFD conditions, or in human MASLD [20,97], is associated with increased hepatic SREBP1c and DNL, whereas IRS1 deletion reduces DNL and TG content without altering SREBP1c levels.”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [97]
In the citing paper
“In humans with MASLD, hepatic IRS2 expression is significantly reduced and correlates with elevated expression of gluconeogenic enzymes, while lipogenic genes such as FASN remain highly expressed and positively correlate with IRS1 levels [97,104].”
From Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications (2025) · cites this paper as [97]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Insulin signalling and the regulation of glucose and lipid metabolism
Saltiel, A. R., & Kahn, C. R. (2001) · Nature · doi:10.1038/414799a · Cited by 5,326 · cited 2×
“Akt-dependent phosphorylation and nuclear exclusion of forkhead boxcontaining protein O subfamily-1 suppress expressions of glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK), resulting in the inhibition of hepatic glucose output [6].”
BackgroundNonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907 · cited 3×
“The histological features of the liver biopsy samples were semi-quantitatively scored according to the Kleiner’s scoring system [22] and Brunt’s staging classification [23] (Table 2).”
BackgroundMethodNonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 3×
“The results were quite similar to those obtained using the classification system developed by Matteoni et al. [21] (Fig.”
MethodInfluentialObesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications
Fabbrini, E., Sullivan, S., & Klein, S. (2010) · Hepatology · doi:10.1002/hep.23280 · Cited by 2,100 · cited 1×
“resistance, which increases the risk of developing type 2 diabetes [3].”
BackgroundDiagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2012) · Diabetes Care · doi:10.2337/dc12-s064 · Cited by 1,491
on behalf of The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension, Ogihara, T., Kikuchi, K., Matsuoka, H., Fujita, T., Higaki, J., Horiuchi, M., Imai, Y., Imaizumi, T., Ito, S., et al. (2014) · Hypertension Research · doi:10.1038/hr.2014.68 · Cited by 1,385 · cited 1×
“The prevalence of hypertension, defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg [29], or taking antihypertensive drugs, also rose with progression of NAFLD (Table 1).”
BackgroundThe Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014)
(2014) · Hypertension Research · doi:10.1038/hr.2014.20 · Cited by 1,049
Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., & Vigneri, R. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0047 · Cited by 1,033 · cited 4×
“isoform in the human liver [46] but IR-A/IR-A [45] and the”
BackgroundInfluential
Cited by
Role of Insulin Resistance in MAFLD
Sakurai, Y., Kubota, N., Yamauchi, T., & Kadowaki, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084156 · Cited by 448
The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
Fujii, H., Kawada, N., & Japan Study Group of NAFLD (JSG-NAFLD) (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113863 · Cited by 299
“examined mRNA expression i 51 human liver biopsy samples obtained from nondiabetic subjects [26].”
BackgroundInfluentialFructose and hepatic insulin resistance
Softic, S., Stanhope, K. L., Boucher, J., Divanovic, S., Lanaspa, M. A., Johnson, R. J., & Kahn, C. R. (2020) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2019.1711360 · Cited by 251
“Obesity increases the risk of developing a myriad of negative health outcomes, including dyslipidemia, hypertension, insulin resistance, type 2 diabetes (T2D) and nonalcoholic fatty liver disease (NAFLD).”
BackgroundInfluentialHepatic lipid droplet homeostasis and fatty liver disease
Seebacher, F., Zeigerer, A., Kory, N., & Krahmer, N. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2020.04.011 · Cited by 190
Besse-Patin, A., Jeromson, S., Levesque-Damphousse, P., Secco, B., Laplante, M., & Estall, J. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815150116 · Cited by 124
“Livers of type 2 diabetic and NAFLD patients are shown to have decreased PGC1A (8–10), correlating with low IRS2 and high IRS1 expression (22, 38).”
Background
Metadata
- Authors
- Honma, M., Sawada, S., Ueno, Y., Murakami, K., Yamada, T., Gao, J., Kodama, S., Izumi, T., Takahashi, K., Tsukita, S., Uno, K., Imai, J., Kakazu, E., Kondo, Y., Mizuno, K., Kawagishi, N., Shimosegawa, T., & Katagiri, H.
- Affiliations
- Tohoku University (JP)
- Yamagata University (JP)
- Tohoku University Hospital (JP)
- Corresponding author
- Sawada, Shojiro
- Katagiri, Hideki
- ORCID
- Venue
- International Journal of Obesity
- Published
- 2018-05-01
- Volume
- 42
- Issue
- 9
- Pages
- 1544-1555
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- PMC
- PMC6160396
- OpenAlex
- W2802224281
- Cited by
- 108
- References
- 50
- Citations by year
- 2026: 5 · 2025: 20 · 2024: 14 · 2023: 10 · 2022: 8 · 2021: 19 · 2020: 19 · 2019: 9 · 2018: 4
- FWCI
- 10.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- International Journal of Obesity (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- Funders
- Japan Society for the Promotion of Science (16K09773, 18H02858, 25253067, 18K16221, 17K09816)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- non-alcoholic fatty liver disease, IRS-1, insulin receptor substrate 2, gluconeogenesis, lipogenesis, fatty acid synthase, hepatic steatosis, nonalcoholic steatohepatitis, liver biopsy, gene expression
- MeSH terms
- Adult, Biopsy, Female, Humans, Insulin Resistance, Liver, Male, Middle Aged, Case-Control Studies, Insulin Receptor Substrate Proteins, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective insulin resistance with differential expressions of IRS-1 and IRS-2 in human NAFLD livers. https://app.cochat.ai/papers/10.1038/s41366-018-0062-9
- The paper
- Honma, M., Sawada, S., Ueno, Y., Murakami, K., Yamada, T., Gao, J., Kodama, S., Izumi, T., Takahashi, K., Tsukita, S., Uno, K., Imai, J., Kakazu, E., Kondo, Y., Mizuno, K., Kawagishi, N., Shimosegawa, T., & Katagiri, H. (2018). Selective insulin resistance with differential expressions of IRS-1 and IRS-2 in human NAFLD livers. International Journal of Obesity. https://doi.org/10.1038/s41366-018-0062-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.